Quantitative genetic variation in CD19 expression correlates with autoimmunity

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6635-6643

  Sato, S ^a   Hasegawa, M ^a   Fujimoto, M ^a   Tedder, T F ^a   Takehara, K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; DNA ANTIBODY; DOUBLE STRANDED DNA; HISTONE; RHEUMATOID FACTOR; SINGLE STRANDED DNA;

ADULT; AGED; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE;

EID: 0034544489     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6635     Document Type: Article

References (46)

1. Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires
2. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity
3. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection
4. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity
5. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes
6. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice
7. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease
8. Molecular basis for the motheaten phenotype
9. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis
10. The signaling activity of murine CD19 is regulated during B cell development
11. CD19 expression levels regulate B lymphocyte development: Human CD19 restores normal function in mice lacking endogenous CD19
12. Studies of in vitro activation and differentiation of human B lymphocytes. 1. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody
13. Tissue-specific expression of the human CD19 gene in transgenie mice inhibits antigen-independent B lymphocyte development
14. CD19 amplifes B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation
15. CD19 regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification
16. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: Altered signaling in CD22-deficient mice
17. The attractions of proteins for small molecules and ions
18. Measurement of specific radioactivities in labelled hormones by self-displacement analysis
19. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule
20. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation
21. Antihistone antibodies in patients with localized scleroderma
22. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
23. Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis
24. The 1982 revised criteria for the classification of systemic lupus erythematosus
25. Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
26. Antibodies to centromere and centriole in scleroderma spectrum disorders
27. Human anticentriole autoantibody in patients with scleroderma and Raynaud's phenomenon
28. Anticentromere and anticentriole antibodies in the scleroderma spectrum
29. Murine models of lupus
30. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop
31. Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19
32. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity
33. Antinuclear antibody in systemic sclerosis (scleroderma)
34. Molecular genetics of systemic sclerosis
35. Increased prevalence of systemic sclerosis in a native American tribe in Oklahoma: Association with an Amerindian HLA haplotype
36. A tandem duplication within the fibrillin I gene is associated with the mouse tight skin mutation
37. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis
38. Immunogenetic associations of scleroderma-related antinuclear antibodies
39. Identification of autoantibodies to RNA polymerase. II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerase I and III
40. Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis
41. Anti-ubiquitin antibody in localized and systemic scleroderma
42. Identification of autoantibodies to the 1 protein of the heterogeneous nuclear ribonucleoprotein complex in patients with systemic sclerosis
43. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis: Possible role of anti-Ela antibody as a serologic indicator for development of primary biliary cirrhosis
44. Antinuclear antibodies and anti-DNA antibodies in scleroderma
45. Early immune events in scleroderma
46. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology